spp complete and capital secured., page-9

I think a total of $2m between the directors is what was proposed and is more realistic.

I would be extremely happy to see that type of investment by directors. $2m each is an extraordinary ask.

I also feel $5m from the SPP, although far from the proposed $15m is a success in this market with the current SP. I wonder how much they actually need to satisfy the grant requirements for these other Ph II trials. maybe they went for $15m with a hope of $5m.

There is a bit of glass half empty instead glass half full sentiment going on. Remembering Prima do have cash in the bank, and this SPP was for Ph II trials for other Mucin 1 expressing cancers.

I have also read the discussion re Dendreon and am surprised. I haven't looked at them for quite a while but they used to be in such a strong financial position with cash levels and reasonably good share registry. The management of Dendreon over the last couple of years appears atrocious.

I feel very strongly that we have a much better product in Cvac in comparison with Provenge and although I haven't looked at the board of Dendreon for a while, I feel we have a very competent board of directors who appear to be focussed on getting Cvac approved, commercialised and marketed.